STOCK TITAN

Alaunos Therapeutics, Inc. - $TCRT STOCK NEWS

Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: $TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.

Alaunos Therapeutics, Inc. (TCRT) is a cutting-edge clinical-stage biopharmaceutical company specializing in cellular immuno-oncology. Focused on the treatment of solid tumors, Alaunos harnesses the power of adoptive TCR-T cell therapy to target Neoantigens that arise from specific genomic mutations. This precision approach aims to improve patient outcomes by striking at the core of cancer cells.

The company employs the latest technologies in cancer research to develop innovative and safer therapeutics. Through its pioneering work, Alaunos strives to offer patients enhanced care and a better quality of life. One of their noteworthy advancements includes the development of TCR engineered cellular therapy targeting RAS-mutant tumors, a prevalent and challenging form of cancer.

Recent achievements highlight Alaunos' commitment to pioneering new solutions. For instance, the company's latest presentation, titled 'Neoantigen Targeting TCR Engineered Cellular Therapy for RAS-mutant Tumors', was showcased on June 30, 2023, by Dr. Collinson-Pautz. This event underscores Alaunos' continuous effort to push the boundaries of cancer treatment through innovative research.

Financially, Alaunos is supported by strong investor relations, managed by Alex Lobo at Stern Investor Relations. Media inquiries are handled by Heather Anderson at 6 Degrees PR, ensuring the company maintains a transparent and engaging communication channel with the public and stakeholders.

In essence, Alaunos Therapeutics Inc. represents the forefront of cancer therapy innovation, dedicated to discovering and developing advanced treatments that offer hope and improved health outcomes for patients battling solid tumors.

Rhea-AI Summary
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) announced an 87% disease control rate in the TCR-T Library Phase 1/2 trial for metastatic solid tumors. The trial showed well-tolerated TCR-T cell therapy with no dose-limiting toxicities. The company's hunTR® platform discovered TCRs recognizing driver mutations, including KRAS and TP53. Alaunos is exploring strategic alternatives to extend cash runway and has reduced its workforce by 80%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
-
Rhea-AI Summary
Alaunos Therapeutics to wind down TCR-T Library trial and focus on hunTR® platform, reducing workforce by 60%
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-64.1%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.95%
Tags
none
Rhea-AI Summary
Alaunos Therapeutics, Inc. announced that they will present early translational data from their ongoing TCR-T Library Phase 1/2 trial at the ASCO Annual Meeting. The data highlights the effectiveness and safety of their non-viral TCR-T cell therapy in treating solid tumors with high-frequency driver mutations. Two out of three patients showed anti-tumor activity, with one achieving a partial response and another achieving stable disease. TCR persistence and tumor infiltration were observed in patients, indicating the potential of this therapy. More data will be provided in the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags

FAQ

What does Alaunos Therapeutics, Inc. specialize in?

Alaunos Therapeutics specializes in cellular immuno-oncology, focusing on the treatment of solid tumors using adoptive TCR-T cell therapy.

What is adoptive TCR-T cell therapy?

Adoptive TCR-T cell therapy is a treatment that involves engineering T cells to target specific Neoantigens from genomic mutations in cancer cells.

What are Neoantigens?

Neoantigens are new antigens that arise due to mutations in cancer cells, making them unique targets for precision therapies like those developed by Alaunos.

What recent advancements has Alaunos made?

Alaunos recently presented their TCR engineered cellular therapy targeting RAS-mutant tumors, highlighting their innovative approach in cancer treatment.

Who manages investor relations for Alaunos Therapeutics?

Investor relations for Alaunos Therapeutics are managed by Alex Lobo at Stern Investor Relations.

How does Alaunos ensure effective communication with stakeholders?

Alaunos maintains effective communication with stakeholders through media inquiries handled by Heather Anderson at 6 Degrees PR.

When was Alaunos' latest presentation on TCR engineered therapy?

Alaunos' latest presentation on TCR engineered therapy was on June 30, 2023.

Who presented the latest research from Alaunos?

The latest research from Alaunos was presented by Dr. Collinson-Pautz.

What is Alaunos' approach to cancer treatment?

Alaunos' approach involves developing precise, safer therapeutics that target specific genomic mutations in cancer cells to improve patient care and quality of life.

How does Alaunos' technology benefit cancer patients?

Alaunos' technology benefits cancer patients by providing more targeted and effective treatments, potentially leading to better outcomes and improved quality of life.

Alaunos Therapeutics, Inc.

Nasdaq:TCRT

TCRT Rankings

TCRT Stock Data

20.58M
13.34M
4.39%
17.14%
9.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
HOUSTON